GentiBio

What if individuals newly diagnosed with Type 1 Diabetes had the opportunity to contribute to cutting-edge research that could change the future of T1D treatment?   GentiBio is actively enrolling participants in the POLARIS Study, a clinical trial designed to investigate a potential approach to slowing or stopping the progression of T1D.   In this video, Kristin Neff, VP of Clinical Operations at GentiBio, shares why this study is close to her heart. Living with Type 1 Diabetes for over three decades, Kristin understands the challenges faced by patients and families, making her perspective on this research especially powerful.   We invite you to watch the video, learn more about the POLARIS Study, and help us spread awareness.   POLARIS Study link: https://lnkd.in/e6uhsMSZ   #Type1Diabetes #T1D #ClinicalTrials #ClinicalResearch #DiabetesResearch #TrialParticipation #AutoimmuneDisease #Biotech #TrialEnrollment

GentiBio is excited to announce that Payam Zarin, Associate Director, will be presenting a poster titled “Modular engineering of Regulatory T cells for the treatment of inflammatory and autoimmune diseases” at the upcoming Immunobiology Gordon Research Conference in Spain. This presentation will include innovative engineering strategies and proof of concept in vivo data showcasing the therapeutic potential of targeted engineered Treg therapies for the treatment of inflammatory and autoimmune diseases.  If you’re attending, keep an eye out for the poster presentation next week; we would welcome the opportunity to connect and discuss further. #GordonResearchConference #Immunobiology #Treg #RegulatoryTCells #CellTherapy #AutoimmuneDisease #Biotech

GentiBio is celebrating 6 years!   From early discovery to now advancing into Phase 1 clinical trials, it’s been an incredible journey. One driven by bold science, persistence, and a shared belief that we can change the way autoimmune diseases are treated.   This milestone belongs to our people. To our scientists, clinicians, engineers, collaborators, and colleagues across operations and support functions: thank you. Your dedication to pushing boundaries, embracing collaboration, and staying grounded in our mission makes this progress possible and brings us closer to making a meaningful difference for patients.   We’re proud of how far we’ve come, and even more motivated by what lies ahead.

We are excited that Mark Bach, CMO at GentiBio, will be presenting on Saturday, June 13 at the 2026 Endocrine Society (ENDO) Annual Meeting. He will share an update from our Phase 1 POLARIS clinical trial of GNTI‑122, highlighting ongoing clinical progress and biomarker strategy in recent-onset type 1 diabetes. We look forward to engaging with the endocrine community and sharing our continued momentum advancing engineered Treg therapies. 🔗 Read the full press release: https://lnkd.in/eY-Y9dvq #ENDO2026 #EndocrineSociety #Type1Diabetes #T1D #ClinicalTrials #Biotech #Phase1Trial

GentiBio recently partnered with ADA TV on an in-depth feature titled: “Stop T1D at the Source” which will be showcased at the 2026 American Diabetes Association Conference starting this week.   In this video filmed by WebsEdge, we highlight the science behind immune imbalance in T1D and how GNTI-122, our engineered regulatory T-cell therapy, is designed to restore immune homeostasis at the source.   We are proud to be featured by ADA TV and to share our novel approach to addressing the root cause of type 1 diabetes. See full video here: https://lnkd.in/eu_d5TgN #Type1Diabetes #T1D #RegulatoryTCells #CellTherapy #TregTherapy #Biotech #LifeSciences #ADA2026 #AmericanDiabetesAssociation

GentiBio is excited to present data from our ongoing HLA Demographics Study at the 2026 ADA Conference this week, and provide insights into type 1 diabetes (T1D) patient genetics and the POLARIS Study of GNTI-122 in recently diagnosed T1D.   Poster P2392 titled “Prevalence of HLA DRB1*04:01 in U.S. Adults with New Onset Type 1 Diabetes (T1D)” | June 8 at 12:30pm CDT Read full Press Release: https://lnkd.in/e6jtAugC Learn more about the POLARIS Study: https://lnkd.in/e6uhsMSZ #type1diabetes #T1D #2026ADA #clinicaltrials #autoimmunedisease #biotech #patientgenetics

GentiBio is excited to continue to advance TCR-based therapies. This week, we are looking forward to hearing Gene Uenishi, Associate Director, present on “Translating TCR-Based Cell Therapies into the Clinic,” including insights on allogeneic TCR-engineered Treg therapies, safety strategies, and regulatory strategy and IND-enabling experience for autologous TCR-based cell therapy programs. #CellTherapy #TCR #Immunotherapy #Biotech #AutoimmuneDisease

#ASGCT2026 kicks off this week, and the GentiBio team is excited to present 9 abstracts, including 5 oral presentations, highlighting advances across our engineered Treg platform and pipeline. See full details here: https://lnkd.in/enReu5Y7   We are looking forward to connecting with the community in Boston this week!

GentiBio is heading to #ASGCT2026 with momentum. We are presenting 9 abstracts (including 5 oral presentations) showcasing progress across our engineered Treg platform, from clinical data in our Phase 1 POLARIS Study to next-generation allogeneic approaches and innovations designed to enhance durability and precision. Together, these data underscore our mission to translate engineered regulatory T cell science into meaningful therapies for autoimmune and inflammatory diseases. 📄 Read the full press release: https://lnkd.in/enReu5Y7 🔗 Learn more about the POLARIS Study: https://lnkd.in/e6uhsMSZ If you are attending ASGCT, we look forward to connecting. #CellTherapy #GeneTherapy #AutoimmuneDisease #Biotech #ClinicalTrials #T1D